Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jie Wang, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
- Beijing Chest Hospital, Capital Medical University
Beijing, Beijing Municipality, China
- Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
- Henan Cancer Hospital
Zhengzhou, Henan, China
- Jiangsu Province Hospital
Nanjing, Jiangsu, China
- Jilin Cancer Hospital
Changchun, Jilin, China
- the First Hospital of Jilin University
Changchun, Jilin, China
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Aug 2017
- Primary completion
- 25 Feb 2019
- Completion
- 21 Dec 2020
- Last update posted
- 23 Oct 2024
- Registered enrollment
- 54
- Registry id
- NCT03432598
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.